Search the Newsreel

Karyopharm Therapeutics has cash to last only into next month

Newton-based biotech Karyopharm Therapeutics is facing a severe cash crisis, with its funding expected to run out within weeks. The company also has a significant debt payment due in September, putting it at risk of default without new financing. Richard Paulson is the CEO …

Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KPTI) 2026-08-13

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Karyopharm Therapeutics: Q2 Earnings Snapshot

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics Inc. announced its Q2 2026 financial results, with total revenue of $33.4 million and U.S. XPOVIO net product revenue of $30.8 million, reaffirming its full-year 2026 revenue guidance. The company remains on track to submit its supplemental New Drug Application (sNDA) in …

Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 1,536,736 shares of Karyopharm Therapeutics Inc. (KPTI) common stock, representing a 6.78% stake. This includes 15,414 shares issuable upon the exercise of warrants. The filing indicates shared …

Karyopharm’s Aug. 13 results call will include slides online

Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second-quarter 2026 financial results on August 13, 2026, including a conference call and live audio webcast with accompanying slides at 8:00 a.m. ET. The company will discuss results and provide updates, with an archived replay …

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the results and provide …

Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview

Karyopharm Therapeutics Inc. is projected to report a loss of $1.28 per share, according to an earnings preview. This information comes from Refinitiv, as reported by Reuters. The full article is available to TradingView subscribers.

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More

Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in underserved regions Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Endometrial Cancer - Market Share Analysis, Industry Trends …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Pomerantz LLP is investigating potential securities fraud claims against Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on behalf of investors. This investigation follows a disclosure by Karyopharm on July 17, 2026, revealing a retention program that awarded top executives significant cash bonuses. Following this news, Karyopharm's …

Myelofibrosis Combo Advances as Karyopharm Preps August sNDA

Karyopharm Therapeutics is preparing an sNDA submission in August 2026 for accelerated approval of its selinexor-ruxolitinib combination therapy for myelofibrosis, based on positive Phase 3 SENTRY trial data showing significant spleen volume reduction. The FDA has accepted SVR35 as a surrogate endpoint for accelerated …

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI)

This article discusses analyst ratings for two healthcare companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI). Teladoc received a "Hold" rating from TD Cowen and Citi, with a consensus price target indicating a modest upside. Karyopharm Therapeutics, on the other hand, received "Buy" ratings from …

Karyopharm Pursues Myelofibrosis FDA Milestone

Karyopharm Therapeutics Inc. (KPTI:NASDAQ) plans to submit a supplemental new drug application (sNDA) to the FDA in August 2026 for accelerated approval of selinexor in combination with ruxolitinib for myelofibrosis, based on positive Phase 3 SENTRY trial data showing significant spleen volume reduction. If …

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. announced it granted 333 restricted stock units (RSUs) to a newly-hired employee on July 31, 2026. This inducement grant, made under Nasdaq Listing Rule 5635(c)(4), will vest over three years, with 33 1/3% vesting annually on the anniversary of the grant …

KARYOPHARM THERAPEUTICS INC : BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $3 FROM $15

Baird has downgraded Karyopharm Therapeutics Inc (KPTI.O) to a Neutral rating and significantly reduced its target price from $15 to $3. This action indicates a revised outlook on the company's financial prospects by the analyst firm. The article, sourced from Reuters, reports this change …

Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer

Karyopharm is re-focusing its efforts on blood cancers after its drug Xpovio failed in a maintenance trial for endometrial cancer. This strategic shift comes as the company adjusts its research and development priorities following the disappointing trial results. The company will now concentrate on …

Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint

Karyopharm Therapeutics' Phase III XPORT-EC-042 clinical trial for selinexor in advanced or recurrent endometrial cancer failed to meet its primary endpoint of progression-free survival. Despite a trend towards improved PFS in the selinexor arm compared to placebo, statistical significance was not reached, leading to …

Karyopharm's Phase 3 Endometrial Cancer Trial Misses Endpoint; Stock Slides

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), announced yesterday topline results from its Phase 3 XPORT-EC-042 trial evaluating Selinexor as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. The study did not meet its primary endpoint of progression free survival, …

Karyopharm Therapeutics INC (KPTI) Q4 2023 Earnings Report - Results, Call & Slides

Karyopharm Therapeutics (KPTI) reported its Q4 2023 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$5.40 against a consensus of -$4.65, and actual revenue of $33.75M compared to an expected $35.41M, although revenue showed a slight YoY increase …

Karyopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA

Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial, testing selinexor maintenance versus placebo, failed to meet its primary progression-free survival (PFS) endpoint. Despite missing this endpoint, the company plans to submit an sNDA in August for accelerated approval of selinexor+ruxolitinib for myelofibrosis, using …

Karyopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval

Karyopharm Therapeutics (KPTI) plans to submit a supplemental New Drug Application (sNDA) in August for accelerated approval of its selinexor-ruxolitinib combination therapy for myelofibrosis. The FDA has agreed that spleen volume reduction (SVR35) can serve as a surrogate endpoint for predicting overall survival, based …

KPTI Stock Craters As Trial Failure And Legal Scrutiny Hit

Karyopharm Therapeutics Inc. (KPTI) shares plunged significantly after its Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer failed to meet its primary endpoint. This clinical setback, coupled with a controversial executive cash retention program that sparked a securities fraud probe by Pomerantz LLP, …

Karyopharm Therapeutics Stock Tanks 68%

Karyopharm Therapeutics Inc. (KPTI) shares plummeted 68% after its Phase 3 XPORT-EC-042 trial failed to meet its primary endpoint of progression-free survival. The stock dropped to $2.2350 from a previous close of $7.01 on Nasdaq. Access to the full article is restricted to subscribers …

Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer

Karyopharm Therapeutics (KPTI) experienced a significant drop in after-hours trading, falling approximately 69%, after its drug Xpovio (selinexor) failed to meet its primary endpoint in a phase 3 trial for endometrial cancer. The trial showed no significant difference in progression-free survival for patients with …

Karyopharm endometrial cancer trial misses primary endpoint By Investing.com

Karyopharm Therapeutics Inc. announced that its Phase 3 XPORT-EC-042 trial for selinexor in advanced or recurrent endometrial cancer failed to meet its primary endpoint of progression-free survival. Although selinexor showed a longer median progression-free survival compared to placebo, the results did not reach statistical …

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Karyopharm Therapeutics Inc. announced topline results from its Phase 3 XPORT-EC-042 trial for selinexor in advanced or recurrent endometrial cancer, which did not meet its primary endpoint of progression-free survival. While a trend favoring the selinexor arm was observed in the mITT population with …

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Karyopharm Therapeutics announced its plan to submit a supplemental New Drug Application (sNDA) to the FDA in August 2026 for selinexor combined with ruxolitinib for myelofibrosis treatment, aiming for accelerated approval. This submission follows positive FDA feedback recognizing spleen volume reduction as a reasonably …

Why Is KPTI Stock Down 69% After-Hours Today?

Karyopharm Therapeutics (KPTI) shares dropped 69% after-hours following the failure of its drug selinexor to meet the primary endpoint in a late-stage trial for endometrial cancer. Despite the setback, the company plans to reduce spending on this program and focus on its myelofibrosis program, …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Be Represent of Investors of Karyopharm Therapeutics Inc. - KPTI

Pomerantz LLP is investigating Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on behalf of investors for potential securities fraud. This investigation follows a significant drop in Karyopharm's stock price after the company disclosed a retention program granting large cash awards to top executives. Investors are encouraged …

Karyopharm Therapeutics Inc (KPTI) Institutional Confidence

Karyopharm Therapeutics Inc (KPTI) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 72.34% quarter-over-quarter to 62.56%. James Simons is the largest institutional shareholder, holding 0.47% of outstanding shares.

KPTI|Karyopharm Therapeutics Inc|Price:6.850|Chg%:-0.240

Karyopharm Therapeutics Inc. (KPTI) shows relatively healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts have recently rated it as "Buy" with a target price of $14.80. Despite a weak …

BlackRock (NASDAQ: KPTI) reports 5.6% ownership of Therapeutics Inc shares

BlackRock, Inc. has disclosed a 5.6% ownership stake in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock through a Schedule 13G SEC filing. This represents 1,266,084 shares, with BlackRock holding sole voting power over 1,251,563 shares and sole dispositive power over all 1,266,084 shares. The …